Pharmaceuticals and Diagnostics

Click here to view our Pharmaceuticals and Diagnostics professionals

Drawing on our strengths in biomedical and chemical matters, we have prosecuted, licensed, and litigated a wide variety of patents in the pharmaceutical and diagnostics fields, including such technologies as:

  • medical diagnostics
  • target discovery
  • high-throughput screening
  • combinatorial chemistry
  • drug-delivery systems
  • therapeutic small molecules
  • drug and antibody assay devices, methods, and reagents.

 

Pharmaceutical patents, and other biotechnology patents generally, are part of our core biotechnology work.

P: 312.913.2104
F: 312.913.0002
P: 312.935.2369
F: 312.913.0002
P: 312.913.2140
F: 312.913.0002
P: 312.913.3357
F: 312.913.0002
P: 312.913.2130
F: 312.913.0002
P: 312.913.2146
F: 312.913.0002
P: 312.913.3330
F: 312.913.0002
P: 312.913.2109
F: 312.913.0002
P: 312.913.2121
F: 312.913.0002
P: 360.379.6514
F: 312.913.2557
P: 312.913.2143
F: 312.913.0002
P: 312.913.3315
F: 312.913.0002
P: 312.913.3333
F: 312.913.0002
P: 312.913.2135
F: 312.913.0002
P: 312.913.3366
F: 312.913.0002
P: 312.913.2116
F: 312.913.0002
P: 312.913.2106
F: 312.913.0002
P: 217.239.1962
F: 312.913.0002
P: 312.913.2123
F: 312.913.0002
P: 312.935.2372
F: 312.913.0002
P: 312.913.3393
F: 312.913.0002
P: 312.913.2129
F: 312.913.0002
P: 312.913.3344
F: 312.913.0002
P: 312.913.2142
F: 312.913.0002
P: 312.913.2126
F: 312.913.0002
P: 312.913.3302
F: 312.913.0002
P: 312.935.2370
F: 312.913.0002
P: 312.913.2145
F: 312.913.0002
P: 312.913.3349
F: 312.913.0002
Associate
P: 312.913.2118
F: 312.913.0002
P: 312.935.2366
F: 312.913.0002
P: 312.913.2133
F: 312.913.0002
P: 312.913.3356
F: 312.913.0002
P: 312.913.2136
F: 312.913.0002
P: 312.913.3348
F: 312.913.0002
P: 312.935.2356
F: 312.913.0002
P: 312.935.2379
F: 312.913.0002
P: 312.913.3368
F: 312.913.0002
Of Counsel
P: 312.913.3362
F: 312.913.0002
P: 312.913.3301
F: 312.913.0002
P: 312.913.2114
F: 312.913.0002
P: 312.913.2132
F: 312.913.0002

Past Event

May 23-24, 2013
MBHB Attorneys James Suggs and Nicole Reifman are Featured Course Leaders for this Management Forum-Sponsored Program
May 17, 2013
MBHB Partner Brad Hulbert is a Featured Co-Presenter at this Management Forum-Sponsored Conference
May 16, 2013
MBHB Partner James McCarthy Is the Featured Presenter
May 16, 2013
MBHB Partner Brad Hulbert is a Featured Co-Presenter at this Management Forum-Sponsored Conference
May 14-16, 2013
MBHB Partners Kevin Noonan and Donald Zuhn are Featured Presenters at this PLI-Sponsored Seminar

Publications

May 20, 2013 (snippets Alert)

On May 20, 2013, new rules of practice and procedure go into effect for International Trade Commission Section 337 Investigations, 19 C.F.R. Parts 201 and 210. Many of these rule changes were made for the purposes of making technical corrections or clarifications to the rules and will have little direct impact upon a complainant or respondent’s strategy in navigating through a Section 337 Investigation. However, some of the changes to the rules, particularly those changes to the rules governing the initiation of an Investigation (§210.12), the termination of an Investigation (§210.21), and the scope of discovery (§210.18), are worthy of attention.

May 14, 2013 (snippets Alert)
The Supreme Court ruled unanimously May 13, 2013 in favor of Monsanto in Bowman v. Monsanto, a case involving Monsanto’s recombinant, Roundup Ready® seeds. The opinion rejected the arguments from petitioner, Indiana farmer Vernon Hugh Bowman, that Monsanto’s rights in its seed had been “exhausted” by their first sale (here, to a grain elevator) and that the Court should reject any “special exception” to the first-sale doctrine of patent exhaustion for “self-replicating technologies.”
Spring 2013 (snippets)
As part of new rules introduced by the Leahy-Smith America Invents Act (AIA), a new section that defines a “micro entity” was added to Title 35 of the United States Code. As a subset of small entity status, micro entity status grants an applicant a seventy-five percent reduction of fees associated with filing, searching, examining, issuing, appealing and maintaining patent applications and patents. The new section sets forth procedures pertaining to claiming micro entity status, paying fees as a micro entity, notifying the United States Patent and Trademark Office (USPTO) of loss of micro entity status, and correcting erroneously paid fees. An applicant has two options for qualifying as a micro entity, which are provided in 35 U.S.C. §§ 123(a) and 123(d) (and implemented in 37 C.F.R. § 1.29). Each is addressed in this article.
Spring 2013 (snippets)
On March 16, 2013, the final (and most significant) portion of the Leahy-Smith America Invents Act (AIA) took effect, and the United States broke from a first-to-invent regime to a first-inventor-to-file (FITF) regime. Of course, this break is far from clean as applications filed before March 16, 2013, as well as certain applications filed after March 15, 2013, will continue to enjoy the advantages of the old first-to-invent system. Since the AIA was enacted on September 16, 2011, the U.S. Patent and Trademark Office (USPTO) has played an important role in implementing the new patent law. In the eighteen months between the statute's enactment and the March 16 effective date, the USPTO published twelve notices of proposed rulemaking, issued a patent trial practice guide, and published a guidance document on the FITF provisions of the AIA, all of which culminated in the revision of the rules of practice in title 37 of the Code of Federal Regulations (C.F.R.). Set forth in this article are a few rule revisions that practitioners should pay careful attention to as we proceed into the FITF regime.
Spring 2013 (snippets)
Since President Obama entered the White House in 2009, his administration has undertaken a number of steps toward stricter policing of international trade secret misappropriation. Those efforts reached a turning point early this year with the release of the “Administration Strategy on Mitigating the Theft of U.S. Trade Secrets.” At the same time, however, news reports have suggested that the Chinese government has facilitated – and even been responsible for – the misappropriation of U.S. trade secrets. As a result, the Obama Administration has ramped up efforts to protect trade secrets against Chinese misappropriation.
Spring 2013 (snippets)
On February 14, 2013, Tiffany filed a lawsuit against Costco Wholesale Corporation (“Costco”), alleging that Costco was engaging in the sale of counterfeit TIFFANY diamond engagement rings. Tiffany’s complaint against Costco alleged violations of federal and New York law, including counterfeiting, trademark infringement, dilution, unfair competition, injury to business reputation, false and deceptive business practices, and false advertising. In its defense and in support of its counterclaims, Costco mainly argued that “[t]he word Tiffany is a generic term for ring settings comprising multiple slender prongs extending upward from a base to hold a single gemstone.”  This article reviews the relative strengths/weaknesses of the main arguments presented by the parties and provides an assessment of which party is more likely to prevail based on the strength of these arguments.
Close
Generate a PDF of your page(s)
Clear
Close
Remove
Page has been queued
An error has occurred
Add
Added to queue
View
Confirm Delete All Message
No Items in Packet Message
To add a page, select Add. To view the package, select View.
false
http://www.mbhb.com/services/xpqServiceDetail.aspx?xpST=ServiceDetail&service=298&pdf=yes
a[href='javascript:packetBuilderSingleClick(document.title);']